{"id":"W4391887693","doi":"10.1016/j.jinf.2024.106120","title":"Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial","year":2024,"lang":"en","type":"letter","venue":"Journal of Infection","topic":"SARS-CoV-2 and COVID-19 Research","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"ca_institutions":"Hotel Dieu Hospital","funders":"Cilag; Fonds Erasme; Gilead Sciences; Conseil Régional, Île-de-France; Celgene; AstraZeneca; European Commission; Amgen; Pfizer; Daiichi Sankyo Europe; Bristol-Myers Squibb","keywords":"Coronavirus disease 2019 (COVID-19); Placebo; Medicine; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Double blind; 2019-20 coronavirus outbreak; Randomized controlled trial; Betacoronavirus; Internal medicine; Virology; Alternative medicine; Pathology; Disease; Outbreak","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001821626,0.0005729335,0.002903944,0.0009429255,0.000158694,0.0002105828,0.0001774388,0.0005669159,0.00003188603],"category_scores_gemma":[0.001056642,0.0002701997,0.002617151,0.0004162792,0.0002467368,0.0002575198,0.00002352318,0.001142617,0.000009766322],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001355004,"about_ca_system_score_gemma":0.002289323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003709724,"about_ca_topic_score_gemma":0.00001783463,"domain_scores_codex":[0.9957036,0.0004064746,0.001695461,0.0003944387,0.00136621,0.0004338047],"domain_scores_gemma":[0.9942869,0.002473972,0.001770115,0.0004243377,0.0009568895,0.00008778458],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9273979,0.002592437,0.0001732864,0.0006622892,0.006497135,0.0002540643,0.0003188656,0.000007910418,0.00004781874,0.000006709439,0.0611437,0.0008978696],"study_design_scores_gemma":[0.6245443,0.0176313,0.000002271243,0.0002247737,0.005706132,0.00008551505,0.000008824736,0.0000978851,0.0004674632,0.0000660641,0.351008,0.000157478],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"commentary","genre_scores_codex":[0.8627926,0.002355363,0.008413377,0.08171321,0.005119182,0.03891115,0.0001422402,0.00006610667,0.0004868078],"genre_scores_gemma":[0.1817605,0.002143785,0.0003017283,0.7596478,0.03706691,0.01471145,0.0004147386,0.0006232356,0.00332978],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.6810321,"threshold_uncertainty_score":0.999975,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04652751616575388,"score_gpt":0.3827364188631838,"score_spread":0.3362089026974299,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}